CLOSTRIDIUM PERFRINGENS TYPE C
LEVELS: Highly unlikely: No controls necessary; Highly unlikely: No evidence of non-foodborne zoonotic transmission; Highly effective: Routine on-farm biosecurity measures are effective in preventing farm-to-farm transmission; Easy: Distinct clinical signs and/or existing test(s) available at local/regional laboratory(s); Substantial: Unsustainable acute or chronic losses related to severe clinical signs in a high prevalence of animals; Negligible: Little or no market disruption when disease occurs on one or more farms; Minimal risk: Agent inherently unlikely to develop clinically important resistance to antibacterial or antiviral treatments; Minimal risk: Antibacterial or antiviral treatments rarely occur, or are typically limited to short-course individual animal therapy; Available but with uncertain efficacy: Limited treatments available in US or are only effective in some situations; Widely available: Effective commercial vaccines widely available in the US (or held in national response stockpile); Highly likely: Can be eradicated using existing tools and knowledge
OVERVIEW
Clostridium perfringens type C is an anaerobic, gram-positive, spore-forming rod that causes fatal necrohemorrhagic enteritis primarily in neonatal piglets worldwide. The disease is characterized by hemorrhagic diarrhea, rapid death, and segmental necrohemorrhagic or fibrinonecrotic enteritis of the small intestine. Type C is distinguished from other C. perfringens types by producing both alpha toxin (CPA) and beta toxin (CPB), with CPB being the main virulence factor. CPB is exquisitely trypsin-sensitive, explaining why neonates are most susceptible—colostrum contains trypsin inhibitors that protect both immunoglobulins and CPB from degradation. Disease typically appears within 12 hours to 1 week of birth, with peracute, acute, and chronic clinical presentations depending on immune status and virulence. In naive herds, epidemics can affect 100% of litters with case fatality rates up to 100% in litters from non-immune gilts; total herd mortality may reach 60%. As sows develop immunity, disease becomes endemic and affects primarily litters of non-immune gilts. Prevention through sow vaccination with type C toxoid is highly effective, typically eliminating disease within one farrowing cycle. Treatment of clinically affected piglets is generally unrewarding.
FOODBORNE ZOONOTIC TRANSMISSION POTENTIAL
Level: Highly unlikely: No controls necessary
C. perfringens type C does not cause foodborne illness in humans from pork products. The chapter notes that C. perfringens type F (formerly CPE+ type A) causes human food poisoning, but type C is not implicated: "Direct contact with swine poses no public health risk associated with C. perfringens type F." Type C infection is specific to neonatal animals with low intestinal trypsin activity.
NON-FOODBORNE ZOONOTIC TRANSMISSION POTENTIAL
Level: Highly unlikely: No evidence of non-foodborne zoonotic transmission
C. perfringens type C is not a zoonotic pathogen. The disease requires specific host conditions (low trypsin activity, colostral trypsin inhibitors) found in neonatal animals. There is no documentation of human infection with C. perfringens type C from contact with infected pigs or contaminated environments.
EFFECTIVENESS OF ON-FARM BIOSECURITY IN PREVENTING FARM-TO-FARM TRANSMISSION
Level: Highly effective: Routine on-farm biosecurity measures are effective in preventing farm-to-farm transmission
Transmission is contained within farms through standard biosecurity and management: (1) Fecal-oral transmission: "Neonatal suckling pigs are infected primarily by exposure to sow feces but may also be infected by horizontal transmission from infected littermates"; (2) Environmental spores: "Spores are resistant to heat, disinfectants, and ultraviolet light" and "may serve as a source of infection for successive litters if the farrowing environment is not sufficiently cleaned and disinfected"; (3) Farm-level control: Disease is controllable through vaccination of sows and sanitation of farrowing facilities; (4) No wildlife reservoir: The organism exists in the environment but disease expression requires specific host conditions. Standard biosecurity combined with vaccination effectively controls the disease within farms.
DIFFICULTY OF DETECTING AND CONFIRMING INFECTION
Level: Easy: Distinct clinical signs and/or existing test(s) available at local/regional laboratory(s)
Diagnosis is typically straightforward based on clinical and pathological findings: (1) Presumptive diagnosis: "hemorrhagic diarrhea and rapid death in neonatal piglets that have gross lesions of segmental necrohemorrhagic or fibrinonecrotic enteritis are sufficient basis for a presumptive diagnosis"; (2) Microscopy: "examination of smears of intestinal mucosa in pursuit of abundant, large, gram-positive rods, mostly non-sporulated, adds confidence"; (3) Toxin detection: "Confirmation of the disease relies on the detection of CPB in intestinal contents or feces"; "Detection of CPB toxin is most commonly performed by antigen immunoassays that are commercially available"; (4) Culture and PCR: "Following culture, genotyping of isolates using a multiplexed PCR assay to detect genes for the major toxins is the nearly universal method"; (5) Sample preservation: "Freezing or adding trypsin inhibitor to intestinal contents or feces prevents proteolysis of CPB for several weeks." Caveat: CPB is trypsin-sensitive, so "failure to detect CPB in intestinal contents does not preclude a diagnosis."
FINANCIAL IMPACT ON FARM'S COST OF PRODUCTION
Level: Substantial: Unsustainable acute or chronic losses related to severe clinical signs in a high prevalence of animals
Type C enteritis causes severe losses in unvaccinated herds: (1) High mortality: "100% mortality in litters of nonimmune gilts is not unusual"; "Total herd mortality may be as high as 60%"; (2) Epidemic potential: "Type C enteritis may occur as epidemics in nonvaccinated populations and can reach a prevalence of 100% of litters"; (3) Endemic losses: When endemic, "peracute, and acute fatal clinical disease is observed predominantly in litters of nonimmune dams, usually gilts"; (4) Rapid death: "Disease may appear as early as 12 hours after birth"; "Many piglets are found dead without observed clinical signs"; (5) Treatment failure: "Treatment is of little value in animals with clinical signs." However, effective vaccination dramatically reduces losses: "Ten-fold reductions in mortality are common" with proper vaccination.
EFFECT ON DOMESTIC OR EXPORT MARKETS
Level: Negligible: Little or no market disruption when disease occurs on one or more farms
C. perfringens type C has minimal market impact: (1) Not regulated: Not a reportable or trade-restricted disease; (2) No trade implications: Disease affects pre-weaning piglets without impacting market-age pigs or pork trade; (3) Farm-level problem: Controllable through routine vaccination programs; (4) Widespread occurrence: "Infection with C. perfringens type C occurs worldwide"—ubiquity means no differentiation by disease status.
PATHOGEN'S ABILITY TO DEVELOP AND SPREAD RESISTANCE
Level: Minimal risk: Agent inherently unlikely to develop clinically important resistance to antibacterial or antiviral treatments
Antimicrobial resistance is minimal: (1) Penicillin susceptibility: "the organism remains uniformly susceptible to penicillins"; (2) Limited resistance reports: "There are reports of antimicrobial resistance in C. perfringens, and tetracycline resistance plasmids have been identified"; (3) Vaccine-based control: Prevention relies on vaccination rather than antimicrobials, reducing selection pressure; (4) Treatment limitations: Treatment rarely used because "Treatment is of little value in animals with clinical signs."
AMR DEVELOPMENT DRIVEN BY DISEASE MANAGEMENT
Level: Minimal risk: Antibacterial or antiviral treatments rarely occur, or are typically limited to short-course individual animal therapy
Disease management primarily relies on vaccination, not antimicrobials: (1) Vaccination preferred: "Prevention is best achieved by vaccination of sows with type C toxoid"; (2) Limited antimicrobial use: "Oral antimicrobials such as ampicillin or amoxicillin can be given prophylactically" in outbreaks, but this is short-term (3 days); (3) Sow medication: "bacitracin methylene disalicylate can be administered to sows before and after farrowing" is optional; (4) Treatment not standard: Clinical treatment is generally unsuccessful, so antimicrobials are not routinely used for disease management.
AVAILABILITY OF EFFECTIVE TREATMENT OPTIONS
Level: Available but with uncertain efficacy: Limited treatments available in US or are only effective in some situations
Treatment options exist but are limited in efficacy once clinical signs appear: (1) Antitoxin: "passive immunization with equine-origin antitoxin can protect piglets in litters of nonimmune sows for up to 21 days" but "CPB antitoxin is not commercially available in most of the world"; (2) Antimicrobials: "Oral antimicrobials such as ampicillin or amoxicillin can be given prophylactically"; "Ceftiofur may be an alternative for the treatment of piglets"; (3) Treatment limitations: "Treatment is of little value in animals with clinical signs"; prophylaxis is the preferred approach; (4) Supportive care: No specific supportive treatments described beyond antimicrobials.
AVAILABILITY OF EFFECTIVE VACCINES OR BACTERINS
Level: Widely available: Effective commercial vaccines widely available in the US (or held in national response stockpile)
Vaccination is highly effective: (1) Commercial vaccines: "Commercial toxoid vaccines are quite effective, and vaccination usually eliminates the disease within one farrowing cycle"; (2) Dramatic efficacy: "Ten-fold reductions in mortality are common"; (3) Protocol: Vaccination "at breeding or mid-gestation and at 2–3 weeks before farrowing"; "Booster injections of vaccine should be given about 3 weeks before subsequent farrowings"; (4) Gilt consideration: "Administering three instead of the two initial recommended vaccine doses before the first farrowing of gilts has been suggested to improve passive protection"; (5) Passive protection: Vaccinated sows provide lactogenic immunity to piglets through colostrum.
FEASIBILITY OF ERADICATING THE DISEASE FROM THE US
Level: Highly likely: Can be eradicated using existing tools and knowledge
Herd-level elimination is readily achievable; national eradication is not pursued because disease is easily controlled: (1) Vaccination eliminates disease: "vaccination usually eliminates the disease within one farrowing cycle"; (2) Environmental control: Thorough cleaning and disinfection of farrowing facilities between litters reduces spore load; (3) No wildlife reservoir: Unlike some other clostridial diseases, no significant wildlife reservoir maintains infection; (4) Practical control: The ease of control through vaccination makes formal eradication programs unnecessary; (5) Ubiquitous organism: C. perfringens exists widely in the environment, but disease expression requires specific conditions easily prevented by vaccination.